Literature DB >> 3638367

Synthesis of complement components (C3, C2, B and C1-inhibitor) and lysozyme by human monocytes and macrophages.

D Lappin, A D Hamilton, L Morrison, M Aref, K Whaley.   

Abstract

The synthesis of C3, C2, factor B (B) C1-inhibitor and lysozyme has been studied in monocytes and macrophages isolated from the synovial fluids of patients with rheumatoid arthritis. Concentrations of all 5 proteins in culture supernatants were measured by the sandwich ELISA technique. Kinetic studies showed that only lysozyme and C3 could be detected in monocyte culture supernatants on the first day of culture, whereas C2, B and C1-inhibitor were not present until the third day. In contrast all 5 proteins could be detected in the supernatants of macrophage cultures on day 1. In both monocyte and macrophage cultures synthesis of lysozyme and C1-inhibitor continued throughout the culture period, whereas synthesis of C2, B and C3 appeared to be reduced after the fifth day in culture. Quantitative studies showed that the secretion rates of lysozyme (4,700 X 10(3) molecules/cell/hr) was similar in monocytes and macrophages. Synthesis rates for all 4 complement components in monocyte cultures were less than 0.2% of that for lysozyme. Although the synthetic rates were higher in macrophages, even then they constituted less than 2% of the rate for lysozyme. Synthetic rates for complement components, but not lysozyme, were increased by BSA-anti-BSA antigen-antibody complexes and reduced by serum-treated complexes. Although the functional activity of monocyte B was similar to that for serum, the activity of monocyte C2 was 5 times that of serum C2. As C42 formed with monocyte C2 had a half-life of 13.5 min at 30 degrees C, compared with 4.5 min for the enzyme formed with serum C2, it is probable that monocyte C2 is oxidized by the oxygen products of these cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3638367

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  12 in total

1.  Modulation of monocyte complement synthesis by interferons.

Authors:  A O Hamilton; L Jones; L Morrison; K Whaley
Journal:  Biochem J       Date:  1987-03-15       Impact factor: 3.857

Review 2.  Complement biosynthesis by mononuclear phagocytes.

Authors:  A R McPhaden; K Whaley
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

3.  Modulation of monocyte complement synthesis by lymphocytes and lymphocyte-conditioned media.

Authors:  D Lappin; K Whaley
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

4.  Modulation by interferons of the expression of monocyte complement genes.

Authors:  D F Lappin; G D Birnie; K Whaley
Journal:  Biochem J       Date:  1990-06-01       Impact factor: 3.857

5.  Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema.

Authors:  J Jackson; R B Sim; K Whaley; C Feighery
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

6.  Complement biosynthesis in human synovial tissue.

Authors:  G J Moffat; D Lappin; G D Birnie; K Whaley
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

7.  Interferon-induced transcriptional and post-transcriptional modulation of factor H and C4 binding-protein synthesis in human monocytes.

Authors:  D F Lappin; K Whaley
Journal:  Biochem J       Date:  1990-11-01       Impact factor: 3.857

8.  Effect of interferon-gamma on complement gene expression in different cell types.

Authors:  D F Lappin; D Guc; A Hill; T McShane; K Whaley
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

9.  Increased C3 production in human monocytes after stimulation with Candida albicans is suppressed by granulocyte-macrophage colony-stimulating factor.

Authors:  A K Høgåsen; T G Abrahamsen
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

10.  Levels of the terminal complement complex, C3a-desArg and C1-inhibitor in adult patients with capillary leak syndrome following bone marrow transplantation.

Authors:  C Salat; E Holler; M Schleuning; B Eisele; B Reinhardt; H Kolb; R Pihusch; R Domrath; E Hiller
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.